II. Indications
- Diabetes Insipidus
- Control of Hemophilia A related bleeding
- Primary Nocturnal Enuresis
- Nocturia (non-medication options are preferred)
-
Von Willebrand's Disease
- Type I (and in Type 2N) cases prior to surgery and in cases of Trauma
- Other VWD forms (Type 2, Type 3 and pseudo-VWF) will not respond to DDAVP
- May have paradoxical lowering of VWF
III. Contraindications
- Impaired Renal Function
- Congestive Heart Failure
IV. Mechanism
- Synthetic ADH replacement Hormone (analogue of Vasopressin)
- Potent antidiuretic
- No Vasopressor activity
- Urine Volume decreases by resorbing water at distal renal tubules
- Increases release of Von Willebrand FactorProtein (stored in Weibel-Palade bodies)
V. Pharmacokinetics
- Duration of action: 12 hours
VI. Dosing: Nocturnal Enuresis
-
General
- If effective, may continue for 3-6 months
- Maintain dose for 4-6 weeks and then slowly taper off over 6 months
- Discontinue slowly (e.g. 10 mcg/month)
- Reduces risk of relapse
- Consider in combination with Bed-Wetting Alarm or Oxybutynin
- Desmopressin Intranasal (standard, high dose)
- Not recommended due to risk of Hyponatremia (from Water Intoxication)
- Initial: 5 mcg spray each nostril qhs
- Increase as needed up to 20 mcg each nostril qhs
- Desmopressin Intranasal (Noctiva, low dose)
- Each spray delivers 0.83 to 1.66 mcg
- Marketed for Nocturia in adults (but other non-medication approaches are preferred)
- Expensive: $425/month in 2018
- Desmopressin Oral
- Initial: 0.2 mg PO qhs
- Use lowest effective dose
- Increase as needed to 0.6 mg at bedtime
VII. Dosing: Diabetes Insipidus
- Nasal Spray: 10-40 mcg daily (or divided 2-3 times per day)
- Intranasal 5 mcg equivalent to 0.1 mg oral
- Oral Tablet: 0.05 to 1.2 mg orally daily (or divided 2-3 times daily)
- Subcutaneous or IV: 2-4 mcg/day IV/SC divided twice daily
VIII. Dosing: Von Willebrand Disease or Hemophilia A
- IV: 0.3 mcg/kg IV over 15 to 30 minutes
- Intranasal concentrated dDAVP (Stimate)
- Weight <50kg: 150 mcg intranasally (1 spray in SINGLE nostril)
- Weight >50kg: 300 mcg intranasally (1 spray EACH nostril)
-
Pharmacokinetics specific to VWF release
- Onset of action within 30-60 minutes with duration of 6-12 hours
- Do not repeat more often than every 24 to 48 hours due to Hyponatremia risk (as well as tachyphylaxis)
IX. Adverse Effects
- Nasal irritation or Epistaxis with nasal spray
- Behavior changes
- Aggressive behavior
- Nightmares
-
Nocturia
- Administer at night to reduce Nocturia
- Severe Hyponatremia (Water Intoxication)
- Seizures (with high dose Desmopressin nasal sprays)
X. Labs
-
Serum Sodium
- Obtain baseline, at 7 days, 30 days and periodically (esp. after dose changes)
XI. Efficacy: Nocturnal Enuresis
- Most effective in over age 8-9 years (60-70% respond)
- Also more effective if only a few wet nights and normal Bladder capacity
- High relapse rate (>80%); Reduced if slowly tapered - see doing above
XII. Disadvantages
- Expensive
- Severe Hyponatremia risk
XIII. Drug Interactions: Increased risk of Hyponatremia
- Diuretics
- Corticosteroids (inhaled or systemic)
- Selective Serotonin Reuptake Inhibitors (SSRI)
- Chronic NSAIDs
XIV. References
- Deloughery and Orman in Majoewsky (2013) EM:Rap 13(9): 1-4
- Tullus (1999) Acta Paediatr 88:1274-8 [PubMed]
- Kruse (2001) BJU Int 88:572-6 [PubMed]
- Robson (2007) J Urol 178: 24-30 [PubMed]
Images: Related links to external sites (from Bing)
Related Studies
desmopressin (on 12/21/2022 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
DESMOPRESSIN 10 MCG/0.1 ML SPR | Generic | $7.86 per ml |
DESMOPRESSIN ACETATE 0.1 MG TB | Generic | $0.33 each |
DESMOPRESSIN ACETATE 0.2 MG TB | Generic | $0.42 each |
Ontology: desmopressin (C0011701)
Definition (NCI) | A synthetic octapeptide, and an analogue of human hormone arginine vasopressin with antidiuretic and coagulant activities. Desmopressin binds to V2 receptors in renal collecting ducts which leads to exocytosis of von Willebrand factor (VWF) and tissue plasminogen activator (t-PA) from Weibel-Palade bodies, thereby increasing water resorption. This agent also increases nitric oxide (NO) production via activation of endothelial NO synthase, thereby induces afferent arteriolar vasodilation. Furthermore, desmopressin stimulates the release of factor VIII from endothelial cells mediated through V1a receptor, thereby promotes blood coagulation. |
Definition (MSH) | A synthetic analog of the pituitary hormone, ARGININE VASOPRESSIN. Its action is mediated by the VASOPRESSIN receptor V2. It has prolonged antidiuretic activity, but little pressor effects. It also modulates levels of circulating FACTOR VIII and VON WILLEBRAND FACTOR. |
Concepts | Pharmacologic Substance (T121) , Hormone (T125) , Amino Acid, Peptide, or Protein (T116) |
MSH | D003894 |
SnomedCT | 126189002, 73454001 |
English | Desmopressin, desmopressin, Deamino Arginine Vasopressin [Chemical/Ingredient], DESMOPRESSIN, Desmopressin preparation, Desmopressin product, Desmopressin (substance), Desmopressin preparation (product), Desmopressin preparation (substance), 1-Deamino-8-D-arginine Vasopressin, 1-Desamino-8-arginine Vasopressin, Arginine Vasopressin, Deamino, Deamino Arginine Vasopressin, Vasopressin, 1-Deamino-8-D-arginine, Vasopressin, 1-Desamino-8-arginine, Vasopressin, Deamino Arginine, Vasopressin, 1-(3-mercaptopropanoic acid)-8-D-arginine- |
Portuguese | Desmopressina, Desamino Arginina Vasopressina, Desaminoarginina Vasopressina |
Spanish | Desmopresina, desmopresina (producto), preparado con desmopresina (producto), preparado con desmopresina, Desamino Arginina Vasopresina, desmopresina (sustancia), desmopresina, preparado de desmopresina (producto), preparado de desmopresina (sustancia), preparado de desmopresina |
Swedish | Argininvasopressin |
Czech | deaminoargininvasopresin, desmopresin |
Finnish | Desmopressiini |
French | Déamino-arginine vasopressine, 1-désamino-8-D-Arginine vasopressine, Desmopressine, 1-Déamino-8-D-arginine vasopressine, Déamino arginine vasopressine, Déamino-D-arginine-vasopressine |
Russian | DESMOPRESSIN, DEZAMINOARGININ-VAZOPRESSIN, VAZOPRESSIN, DEZAMINOARGININ, DDAVP, ВАЗОПРЕССИН, ДЕЗАМИНОАРГИНИН, ДЕЗАМИНОАРГИНИН-ВАЗОПРЕССИН, ДЕСМОПРЕССИН |
Japanese | デアミノアルギニンバソプレシン, デスモプレシン, 1-デスアミノ-8-アルギニンバソプレシン, 酢酸デスモプレシン |
Italian | 1-Deamino-8-D-arginina vasopressina, 1-Deamino-8-arginina vasopressina, Desmopressina, Deamino arginina vasopressina |
Polish | Adiuretyna, Desmopresyna |
Norwegian | 1-deamino-8-D-arginin- vasopressin, Desmopressin, Deaminoarginin-vasopressin, Vasopressin, deaminoarginin, 1-desamino-8-arginin- vasopressin |
German | Desaminoarginin-Vasopressin, Vasopressin, Desaminoarginin-, 1-Deamino-8-D-Arginin-Vasopressin, 1-Desamino-8-Arginin-Vasopressin, Deamino-Arginin-Vasopressin, Vasopressin, Deamino-Arginin- |
Ontology: DDAVP (C0701195)
Concepts | Pharmacologic Substance (T121) , Amino Acid, Peptide, or Protein (T116) , Hormone (T125) |
MSH | D003894 |
English | Desmospray, Desmotabs, Desmopressine Ferring, Ferring, Desmopressine, Octim, Octostim, DDAVP, Ferring Brand 1 of Desmopressin Acetate, ddavp |
Czech | DDAVP |
French | DDAVP |
German | DDAVP |
Norwegian | DDAVP |